We have been instrumental in developing SPC case law, with high-value wins for our clients in the UK High Court and Court of Appeal, and before the Court of Justice of the European Union.
Clients seek us out especially for our experience with contentious SPC proceedings and our ability to provide comprehensive and insightful advice in this area. We regularly appeal adverse SPC decisions up through the courts across Europe. We have been at the forefront of developments in European SPC law from the very beginning.
Over the past two decades, our attorneys have been entrusted with high-value SPC cases for innovative products before the Court of Justice of the European Union such as ABRAXANE® (C-443/17 Abraxis Bioscience), CERVARIX® and GARDASIL® (C-630/10 University of Queensland and CSL), CIRCADIN® (C-130/11 Neurim Pharmaceuticals) and ILARIS® (C-354/19 Novartis).
We report and comment on new developments of SPC law on a regular basis. Our SPC summer review has become a yearly fixture in the journal of the Chartered Institute of Patent Attorneys, and our companion event hosted in our London office attracts preeminent speakers and audiences from law firms, patent departments and patent offices alike.